// App-Quantinova.ai

: Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Matthew T. Campbell

  • Boris Y. Alekseev

  • Motohide Uemura

  • Christian K. Kollmannsberger

  • Gwenaelle Gravis

  • Georg A. Bjarnason

  • Howard Gurney

  • Jinsoo Chung

  • John B. A. G. Haanen

  • Brian I. Rini

  • James M. G. Larkin

  • Manuela Schmidinger

  • Franco Nole

  • Aleksander Chudnovsky

  • Bo Huang

  • Subramanian Hariharan

  • Alessandra di Pietro

  • Laurence Albiges

Medical Centers

  • The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Moscow Scientific Research Oncology Institute, Moscow, Russian Federation

  • Osaka University Hospital, Suita, Japan

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Institut Paoli-Calmettes, Marseille, France

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Macquarie University Hospital, Sydney, Australia

  • National Cancer Center, Goyang-si, Korea, Republic of.

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Cleveland Clinic, Cleveland, OH

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Medical University Vienna, Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Vienna, Austria

  • Istituto Europeo Di Oncologia Medical Oncology Division of Urogenital and Head & Neck Tumours, Milano, Italy

  • Pfizer Inc., Cambridge, MA

  • Pfizer, Groton, CT

  • Pfizer Inc, New York, NY

  • Pfizer Inc., Lombardia, Italy

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • United States

  • Russia

  • Japan

  • Canada

  • France

  • Australia

  • Netherlands

  • United Kingdom

  • Austria

  • Italy

  • Republic of South Korea

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Sunitinib

  • Inlyta

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02684006

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved